Amgen (AMGN) Competitors

Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Do analysts prefer GILD or AMGN?

Gilead Sciences currently has a consensus price target of $111.38, indicating a potential upside of 2.37%. Amgen has a consensus price target of $307.82, indicating a potential upside of 3.21%. Given Amgen's higher probable upside, analysts plainly believe Amgen is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	9 Hold rating(s)	14 Buy rating(s)	3 Strong Buy rating(s)	2.77
Amgen	2 Sell rating(s)	12 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.35

Is GILD or AMGN a better dividend stock?

Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 2.9%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Gilead Sciences pays out 66.5% of its earnings in the form of a dividend. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences has increased its dividend for 10 consecutive years and Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Which has stronger valuation and earnings, GILD or AMGN?

Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$28.75B	4.71	$480M	$4.75	22.91
Amgen	$33.42B	4.80	$4.09B	$10.96	27.21

Which has more volatility and risk, GILD or AMGN?

Gilead Sciences has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500.

Is GILD or AMGN more profitable?

Gilead Sciences has a net margin of 20.76% compared to Amgen's net margin of 17.39%. Amgen's return on equity of 176.11% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	20.76%	51.93%	17.40%
Amgen	17.39%	176.11%	12.39%

Do insiders and institutionals hold more shares of GILD or AMGN?

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 0.8% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the media favor GILD or AMGN?

In the previous week, Gilead Sciences had 3 more articles in the media than Amgen. MarketBeat recorded 68 mentions for Gilead Sciences and 65 mentions for Amgen. Amgen's average media sentiment score of 1.42 beat Gilead Sciences' score of 0.86 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	37 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Amgen	54 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amgen beats Gilead Sciences on 12 of the 20 factors compared between the two stocks.